Teva Pharmaceutical Industries (TEVA) lists vested awards and a 447,678-share sale
Rhea-AI Filing Summary
Teva Pharmaceutical Industries Limited submitted a Form 144 reporting proposed sales of ordinary shares through Citigroup Global Markets Inc., with transactions and vested compensation-related shares listed and one recent sale reported. The filing lists vested awards scheduled 03/03/2026 and a sale by Richard Francis on 02/17/2026 for 447,678 shares with amount 15324799.05.
Positive
- None.
Negative
- None.
Insights
Notice of proposed resale activity for ordinary shares; procedural disclosure.
The form lists proposed sales routed through Citigroup Global Markets Inc. and identifies compensation awards vesting on 03/03/2026 (quantities: 67,231, 697,211, 194,104). The document includes a reported sale of 447,678 shares on 02/17/2026 with amount 15324799.05.
These disclosures are procedural notices required for resale; the filing does not state routing mechanics, pricing method, or who receives proceeds beyond the listed broker. Subsequent filings would show execution details if and when sales occur.
Compensation-related share vesting and a recent large sale are recorded; market impact not assessed here.
The excerpt shows multiple compensation awards vesting on 03/03/2026 totaling listed share counts and a prior reported sale by Richard Francis of 447,678 shares on 02/17/2026. The broker named is Citigroup Global Markets Inc.
Timing and sale methods are not detailed in the excerpt; actual market impact depends on execution, which is not disclosed in this excerpt.